Precede Biosciences
Precede Biosciences is a biotechnology company that developed a blood test to analyze disease-related gene activity, with 64 employees and $141M in total funding. Its Series B round closed in January 2026, backed by investors including 5AM Ventures and Bristol-Myers Squibb. Precede Biosciences provides a genome-wide platform that profiles chromatin and DNA methylation from blood samples to identify disease-related gene activity. Its technology aims to improve drug development success rates by offering insights into disease biology. The company partners with pharmaceutical developers and advances its own diagnostic tests. The company has raised $141M, including a Series B in 2026, and employs 64 people. Its funding and partnerships with major players like Bristol-Myers Squibb and LabCorp suggest strong industry validation and growth potential.
The growth story
Precede Biosciences grew from 7 to 64 employees between 2021 and 2026, raising $141M along the way, most recently a Series B in January 2026.
About
We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, Precede Bio developed a simple blood test to uncover actionable disease-defining transcriptional biology. Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma. By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where
Founders and leadership
Precede Biosciences is led by a team with expertise in biotechnology and diagnostics, with its largest function being Research, which accounts for 15 employees. The company’s leadership likely draws from its top talent sources, including Foundation Medicine and Thrive Earlier Detection.
The Precede Biosciences org chart
Rehan Verjee (Co-founder and CEO) leads 26 mapped leaders with 4 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 25 (0% YoY), Business Development 19 (+58% YoY), Engineering 5 (+25% YoY).
Talent flow
Precede Biosciences recruits heavily from Foundation Medicine and Thrive Earlier Detection, with 13 and 10 hires respectively. Its employees also come from AstraZeneca, Broad Institute, and Exact Sciences. Alumni have moved to roles at AstraZeneca, Crossbow Therapeutics, and academic institutions like Northeastern University.
Most common previous employers of Precede Biosciences staff: Foundation Medicine (13), Thrive Earlier Detection (10), AstraZeneca (5), 4:59 NewCo, a 5AM Ventures Company (5), Broad Institute of MIT and Harvard (5), Exact Sciences (4). Former Precede Biosciences employees most often moved to Even One Ventures (1), AstraZeneca (1), Crossbow Therapeutics (1), 5AM Ventures (1), Northeastern University (1), NewYork-Presbyterian Hospital (1).
Web traffic
Traffic mix: 81% direct, 15% search, 0% social, 0% paid.
What this company is made of
Most common skills at Precede Biosciences: Molecular Biology (29), Biotechnology (29), Life Sciences (25), Bioinformatics (22), Genomics (21), Cell Culture (20), Assay Development (18), Data Analysis (18).
Where the team actually sits
Precede Biosciences people are concentrated in Massachusetts, United States (31), Greater Boston (14), United States (2), Texas, United States (1).
Search footprint
Precede Biosciences attracts about 4,562 organic search visits a month, traffic worth roughly $1K a month if bought through ads. It gained 28 ranking keywords and lost 20 in the last period.
Frequently asked
Precede Biosciences has 64 employees as of September 2026.
Precede Biosciences has raised $141M in total, most recently a Series B round in January 2026.
Precede Biosciences was founded in 2021 by Rehan Verjee, Sylvan Baca.
Rehan Verjee (Co-founder and CEO) sits at the top of Precede Biosciences's reporting structure, with 4 direct reports.
The most common previous employers of current Precede Biosciences staff are Foundation Medicine (13 people), Thrive Earlier Detection (10 people), AstraZeneca (5 people).
Former Precede Biosciences employees most often move to Even One Ventures (1), AstraZeneca (1), Crossbow Therapeutics (1).
Precede Biosciences attracts about 4,562 organic search visits a month, worth roughly $1K a month in equivalent ad spend.
The most common skills among Precede Biosciences staff are Molecular Biology, Biotechnology, Life Sciences, Bioinformatics, Genomics.
Precede Biosciences staff are concentrated in Massachusetts, United States (31), Greater Boston (14), United States (2).
Precede Biosciences has about 25 people in Research, up 0% over the past year, as of September 2026.
Precede Biosciences has about 19 people in Business Development, up 58% over the past year, as of September 2026.
Computed from 52 current and 16 former Precede Biosciences profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.